Focused on developing treatments for rare diseases mediated by the complement system. Acquired by Bioverativ in 2017.
True North Therapeutics
Life Sciences, Venture Debt
Focused on developing treatments for rare diseases mediated by the complement system. Acquired by Bioverativ in 2017.